Third Harmonic Bio Inc’s recent filing unveils that its Chief Medical Officer Conner Edward R. unloaded Company’s shares for reported $31755.0 on Nov 08 ’24. In the deal valued at $15.00 per share,2,117 shares were sold. As a result of this transaction, Conner Edward R. now holds 0 shares worth roughly $0.0.
Then, BVF PARTNERS L P/IL sold 1,000,000 shares, generating $14,300,000 in total proceeds. Upon selling the shares at $14.30, the See Explanation of Responses now owns 176,692 shares.
Before that, Conner Edward R. sold 2,673 shares. Third Harmonic Bio Inc shares valued at $40,095 were divested by the Chief Medical Officer at a price of $15.00 per share. As a result of the transaction, Conner Edward R. now holds 0 shares, worth roughly $0.0.
Stifel downgraded its Third Harmonic Bio Inc [THRD] rating to a Hold from a a Buy in a research note published on March 28, 2025; the price target was decreased to $5 from $23. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in mid February from “an Overweight” to “an Equal-weight”. Raymond James also remained covering THRD and has decreased its forecast on February 11, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Morgan Stanley revised its rating on August 09, 2024. It rated THRD as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of THRD
On Tuesday, Third Harmonic Bio Inc [NASDAQ:THRD] saw its stock fall -0.19% to $5.15. Third Harmonic Bio Inc shares have fallen nearly -49.95% since the year began. Nevertheless, the stocks have fallen -58.13% over the past one year. While a 52-week high of $16.94 was reached on 01/03/25, a 52-week low of $3.18 was recorded on 02/11/25. SMA at 50 days reached $4.20, while 200 days put it at $9.00.
Levels Of Support And Resistance For THRD Stock
The 24-hour chart illustrates a support level at 5.12, which if violated will result in even more drops to 5.10. On the upside, there is a resistance level at 5.18. A further resistance level may holdings at 5.22. The Relative Strength Index (RSI) on the 14-day chart is 75.97, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.46%. Stochastics %K at 29.95% indicates the stock is a holding.
The most recent change occurred on June 18, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $23 price target.
